Cargando…
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks
Sapacitabine is an orally bioavailable prodrug of the nucleoside analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine (CNDAC). Both the prodrug and active metabolite are in clinical trials for hematologic malignancies and/or solid tumors. CNDAC has a unique mechanism of action: after inco...
Autores principales: | Liu, Xiao-Jun, Nowak, Billie, Wang, Ya-Qing, Plunkett, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3777512/ https://www.ncbi.nlm.nih.gov/pubmed/22739266 http://dx.doi.org/10.5732/cjc.012.10077 |
Ejemplares similares
-
Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine
por: Jagan, Sucheta, et al.
Publicado: (2012) -
The Dipeptide Monoester Prodrugs of Floxuridine and Gemcitabine—Feasibility of Orally Administrable Nucleoside Analogs
por: Tsume, Yasuhiro, et al.
Publicado: (2014) -
Nucleoside analogs in ADAR guide strands targeting 5′-UA̲ sites
por: Brinkman, Hannah F., et al.
Publicado: (2022) -
Synthesis of Nucleoside Phosphate
and Phosphonate
Prodrugs
por: Pradere, Ugo, et al.
Publicado: (2014) -
Advances in antiviral nucleoside analogues and their prodrugs
por: Seley-Radtke, Katherine, et al.
Publicado: (2018)